Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia

Clinical Chemistry

Volumn 53, Issue 12, 2007, Pages 2193-2201

  Masiá, Mar ^a   Papassotiriou, Jana ^b   Morgenthaler, Nils G ^b   Hernández, Ildefonso ^c   Shum, Conrado ^a   Gutiérrez, Félix ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b BRAHMS AG   (Germany)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LIPOPOLYSACCHARIDE; NATRIURETIC FACTOR; PROCALCITONIN; VASOPRESSIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK ASSESSMENT; SERUM; STATISTICAL SIGNIFICANCE; SURVIVAL; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; VASOPRESSINS;

EID: 36649016435     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.085688     Document Type: Article

References (33)

1. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
2. Ewig S, De Roux A, Bauer T, Garcia E, Mensa J, Niederman M, et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004;59:421-7.
3. Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006;27:9-11.
4. Angus DC, Marrie TJ, Obrosky S, Clermont G, Dremsizov TT, Coley C, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of the American and British Thoracic Society criteria. Am J Respir Crit Care Med 2002;166:717-23.
5. Masia M, Gutierrez F, Shum C, Padilla S, Navarro JC, Flores E, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005;128:2223-9.
6. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180:1584-9.
7. Masia M, Gutierrez F, Llorca B, Navarro JC, Mirete C, Padilla S, et al. Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem 2004;50:1661-4.
8. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin-guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93.
9. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000;28:68-73.
10. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular diseases. Clin Sci 1998;95:519-29.
11. Potter LR. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006;27:47-72.
12. Hoffmann U, Brueckmann M, Bertsch T, Wiessner M, Liebetrau C, Lang S, et al. Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Clin Lab 2005;1:373-9.
13. Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiss C, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005;112:527-34.
14. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Muller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005;9:R37-45.
15. Muller B, Suess E, Schuetz P, Muller C, Bingisser R, Bergmann A, et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006;260:568-76.
16. Asfar P, Hauser B, Radermacher P, Matejovic M. Catecholamines and vasopressin during critical illness. Crit Care Clin 2006;22:131-49.
17. De Bree FM, Burbach JP. Structure-function relationship of the vasopressin prohormone domains. Cell Mol Neurobiol 1998;18:173-91.
18. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2002;46:1785-91.
19. Jochberger S, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schmid S, et al. Serum vasopressin concentrations in critically ill patients. Crit Care Med 2006;34:293-9.
20. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-9.
21. Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci 1999;97:689-95.
22. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983;5:1129-38.
23. Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F. Improved extraction procedure and RIA for determination of arginine8-vasopressin in plasma: role of premeasurement sample treatment and reference values in children. Clin Chem 1999;45:98-103.
24. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234-6.
25. Gutierrez F, Masiá M, Rodriguez JC, Ayelo A, Soldan B, Cebrian L, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003;36:286-92.
26. Gutiérrez F, Masiá M, Rodríguez JC, Mirete C, Soldan B, Padilla S, et al. Epidemiology of community-acquired pneumonia in adult patients at dawn of the twenty-first century: a prospective study at the Mediterranean coast of Spain. Clin Microbiol Infect 2005;11:788-800.
27. Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002;8:93-100.
28. Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 2005;258:391-3.
29. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006;10:R96.
30. Hogenhuis J, Voors AA, Jaarsma T, Hillege HL, Boomsma F, van Veldhuisen DJ. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur J Heart Fail 2005;7:81-6.
31. Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science 1997;278:419-24.
32. Dietz J. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res 2005;68:8-17.
33. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989-1002.